Internally Sponsored Programs
Enteris BioPharma’s internal clinical pipeline of products are being evaluated and include Ovarest® for endometriosis and Tobrate™ for uUTIs.
Enteris BioPharma is enhancing the value of its Peptelligence® oral drug delivery platform by developing an innovative internal clinical pipeline of orally delivered therapeutics that have been previously marketed as injectable-only formulations. Enteris has developed a strong regulatory strategy involving the use of the 505(b)(2) regulatory pathway, allowing the company to take advantage of existing safety data. External market analyses demonstrate projected annual U.S. revenue potential for these two products approximate $1 billion in the aggregate.
Find out how to partner with Enteris BioPharma’s internal clinical programs
Externally Sponsored Programs
Enteris BioPharma’s oral peptide and small molecule delivery technology has been applied to a range of molecules across multiple therapeutic areas.
The technology is the subject of several active externally sponsored pre-clinical and clinical development programs, the most advanced of which include R-Pharm’s TBRIA, an oral calcitonin for patients with postmenopausal osteoporosis, and an oral formulation of Cara Therapeutics’ KORSUVA™, a potent peripheral kappa opioid receptor agonist with a primary focus for the treatment of pruritus.
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ENTERIS BIOPHARMA
(0ral Leuprolide Tablet)
(Oral Tobramycin Tablet)
CARA THERAPEUTICS
(oral CR845)
(oral CR845)
(oral CR845)